Anti-β2-glycoprotein I antibody

Specificity and clinical significance

T. Koike, Eiji Matsuura

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cardiolipin binding of IgG-class anticardiolipin antibody (aCL) depends on the existence of β2-glycoprotein I (β2-GPI). We developed an EIA system that enables detection of antibodies against β2-GPI, without the presence of cardiolipin. This system involves use of irradiated polystyrene plates, in which oxygen atoms are introduced onto the surfaces of the plates. β2-GPI bound to the surface of these plates is assumed to undergo a conformational change that exposes normally cryptic epitopes. Anti-β2-GPI antibody measured using this EIA system showed good correlation with aCL measured by conventional EIA methods and may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE. Utilizing this EIA system and β2-GPI-deleted mutants, we found that the fourth domain of β2-GPI is involved in expression of one of the cryptic epitopes recognized by aCL. We also found that oxidized LDL are sequentially targeted by β2-GPI and aCL.

Original languageEnglish
Pages (from-to)378-380
Number of pages3
JournalLupus
Volume5
Issue number5
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Antibody Specificity
Glycoproteins
Anticardiolipin Antibodies
Cardiolipins
Epitopes
Antibodies
Polystyrenes
Thrombosis
Immunoglobulin G
Oxygen

Keywords

  • β-glycoprotein I
  • Anti-β-glycoprotein I antibody
  • Anticardiolipin antibody

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Anti-β2-glycoprotein I antibody : Specificity and clinical significance. / Koike, T.; Matsuura, Eiji.

In: Lupus, Vol. 5, No. 5, 1996, p. 378-380.

Research output: Contribution to journalArticle

@article{d450e951c71e4edebfbe4bbd04538b35,
title = "Anti-β2-glycoprotein I antibody: Specificity and clinical significance",
abstract = "Cardiolipin binding of IgG-class anticardiolipin antibody (aCL) depends on the existence of β2-glycoprotein I (β2-GPI). We developed an EIA system that enables detection of antibodies against β2-GPI, without the presence of cardiolipin. This system involves use of irradiated polystyrene plates, in which oxygen atoms are introduced onto the surfaces of the plates. β2-GPI bound to the surface of these plates is assumed to undergo a conformational change that exposes normally cryptic epitopes. Anti-β2-GPI antibody measured using this EIA system showed good correlation with aCL measured by conventional EIA methods and may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE. Utilizing this EIA system and β2-GPI-deleted mutants, we found that the fourth domain of β2-GPI is involved in expression of one of the cryptic epitopes recognized by aCL. We also found that oxidized LDL are sequentially targeted by β2-GPI and aCL.",
keywords = "β-glycoprotein I, Anti-β-glycoprotein I antibody, Anticardiolipin antibody",
author = "T. Koike and Eiji Matsuura",
year = "1996",
language = "English",
volume = "5",
pages = "378--380",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Anti-β2-glycoprotein I antibody

T2 - Specificity and clinical significance

AU - Koike, T.

AU - Matsuura, Eiji

PY - 1996

Y1 - 1996

N2 - Cardiolipin binding of IgG-class anticardiolipin antibody (aCL) depends on the existence of β2-glycoprotein I (β2-GPI). We developed an EIA system that enables detection of antibodies against β2-GPI, without the presence of cardiolipin. This system involves use of irradiated polystyrene plates, in which oxygen atoms are introduced onto the surfaces of the plates. β2-GPI bound to the surface of these plates is assumed to undergo a conformational change that exposes normally cryptic epitopes. Anti-β2-GPI antibody measured using this EIA system showed good correlation with aCL measured by conventional EIA methods and may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE. Utilizing this EIA system and β2-GPI-deleted mutants, we found that the fourth domain of β2-GPI is involved in expression of one of the cryptic epitopes recognized by aCL. We also found that oxidized LDL are sequentially targeted by β2-GPI and aCL.

AB - Cardiolipin binding of IgG-class anticardiolipin antibody (aCL) depends on the existence of β2-glycoprotein I (β2-GPI). We developed an EIA system that enables detection of antibodies against β2-GPI, without the presence of cardiolipin. This system involves use of irradiated polystyrene plates, in which oxygen atoms are introduced onto the surfaces of the plates. β2-GPI bound to the surface of these plates is assumed to undergo a conformational change that exposes normally cryptic epitopes. Anti-β2-GPI antibody measured using this EIA system showed good correlation with aCL measured by conventional EIA methods and may prove useful in evaluating the risk of thrombosis and monitoring the clinical course in patients with SLE. Utilizing this EIA system and β2-GPI-deleted mutants, we found that the fourth domain of β2-GPI is involved in expression of one of the cryptic epitopes recognized by aCL. We also found that oxidized LDL are sequentially targeted by β2-GPI and aCL.

KW - β-glycoprotein I

KW - Anti-β-glycoprotein I antibody

KW - Anticardiolipin antibody

UR - http://www.scopus.com/inward/record.url?scp=0029805043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029805043&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 378

EP - 380

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -